



# UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office  
Address: COMMISSIONER FOR PATENTS  
P.O. Box 1450  
Alexandria, Virginia 22313-1450  
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/749,538	12/30/2003	Akito Nakamura	350292000402	8856
25225 7590 10/19/2007 MORRISON & FOERSTER LLP 12531 HIGH BLUFF DRIVE SUITE 100 SAN DIEGO, CA 92130-2040			EXAMINER YU, MISOOK	
			ART UNIT 1642	PAPER NUMBER
			MAIL DATE 10/19/2007	DELIVERY MODE PAPER

**Please find below and/or attached an Office communication concerning this application or proceeding.**

The time period for reply, if any, is set in the attached communication.



**UNITED STATES DEPARTMENT OF COMMERCE  
U.S. Patent and Trademark Office**

Address: COMMISSIONER FOR PATENTS  
P.O. Box 1450  
Alexandria, Virginia 22313-1450

APPLICATION NO./ CONTROL NO.	FILING DATE	FIRST NAMED INVENTOR / PATENT IN REEXAMINATION	ATTORNEY DOCKET NO.
10749538	12/30/2003	NAKAMURA ET AL.	350292000402

MORRISON & FOERSTER LLP  
12531 HIGH BLUFF DRIVE  
SUITE 100  
SAN DIEGO, CA 92130-2040

EXAMINER

MISOOK YU

ART UNIT	PAPER
1642	20071015

DATE MAILED:

**Please find below and/or attached an Office communication concerning this application or proceeding.**

**Commissioner for Patents**

Interview request is noted. Applicant is kindly requested to call the undersigned (571-272-0839) at least one week prior to the desired interview date to make interview appointment.

The reply filed on 7/13/2007 is not fully responsive to the prior Office Action because of the following omission(s) or matter(s): Applicant in the response elected antibody. However, the species in the 2nd Restriction/Election Requirement mailed on 05/31/2007 are as follows: orally, intravenous injection, drip infusion, intraarterial injection, intramuscular injection, intratumor injection, intrathoracic injection, or intraperitoneal injection, subcutaneous injection, local dosage-forms, external preparations, local injections, liniments, ointments, gel, cream, emulsions, and liquids, tapes, plaster tapes, patches, nebulas, sprays or powders. See 37 CFR 1.111. Since the above-mentioned reply appears to be bona fide, applicant is given ONE (1) MONTH or THIRTY (30) DAYS from the mailing date of this notice, whichever is longer, within which to supply the omission or correction in order to avoid abandonment. EXTENSIONS OF THIS TIME PERIOD MAY BE GRANTED UNDER 37 CFR 1.136(a).

/Misook Yu/  
MISOOK YU  
Primary Examiner  
Art Unit: 1642